The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept

Clinical and Experimental Dermatology

Volumn 36, Issue 8, 2011, Pages 845-850

  Kanelleas, A ^a   Liapi, C ^b   Katoulis, A ^a   Stavropoulos, P ^b   Avgerinou, G ^b   Georgala, S ^b   Economopoulos, T ^c   Stavrianeas, N G ^a   Katsambas, A ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Second Department of Internal Medicine   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CERULOPLASMIN; ETANERCEPT; FERRITIN; FIBRINOGEN; HAPTOGLOBIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE; MALE; NEUTROPHIL; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 81255158675     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04131.x     Document Type: Article

References (13)

1. Griffiths CEM, Barker JNWN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71. (Pubitemid 47069537)
2. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41. (Pubitemid 44547793)
3. Nickoloff BJ,. Cracking the cytokine code in psoriasis. Nat Med 2007; 13: 242-4. (Pubitemid 46376653)
4. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
5. Rashmi R, Rao KSJ, Basavaraj KH,. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009; 34: 658-63.
6. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-28. (Pubitemid 38903524)
7. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-30. (Pubitemid 352009830)
8. Pathirana D, Ormerod AD, Saiag P, et al. European S3 guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 34-8.
9. Warren JS, Ward PA, Johnson KJ, et al. The inflammatory response. In: Hematology, 4th edn (, Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds). New York: McGraw-Hill, 1990: 63-70.
10. Karabudak O, Ulusoy RE, Erikci AA, et al. Inflammation and hypercoaguable state in adult psoriatic men. Acta Derm Venereol 2008; 88: 337-40. (Pubitemid 352029507)
11. Spah F,. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008; 159 (Suppl. 2): 10-17.
12. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
13. Mönig H, Marquardt D, Arendt T, et al. Limited value of elevated erythrocyte sedimentation rate as an indicator of malignancy. Fam Pract 2002; 19: 436-8. (Pubitemid 35244223)